Peptide Decoding
New?New to peptides?Start here →
Decoding

Bevemipretide (SBT-272)_Dosage, benefits & legal status

Corrected November 21, 2026: Bevemipretide

Also known as SBT-272, SBT272, SBT 272, bevemipretide trihydrochloride, bevemipretide eye drops

Published November 21, 2026

A three-residue mitochondrial peptide with a ring where its tail should be.

Restore mitochondrial functionMitochondria-targeted peptidomimetic (eye drop; injected in the phase 1)Investigational
Dose1 percent or 2 percent eye drops once daily (phase 2/3)
FrequencyOnce daily in the study eye
RouteA once-daily ophthalmic topical solution in the current trial; subcutaneous injection in the completed phase 1
StatusInvestigational
CycledNot established

See how this dose compares across the library →

01

What is Bevemipretide (SBT-272)?

Plain language first. The technical label stays, but it never stands alone.

Overview

A redesigned mitochondria peptide built to reach the brain, still unproven in people.

The technical version

A brain-penetrant cardiolipin-binding peptidomimetic of three residues, two non-standard, with a benzyl-oxadiazole bioisostere at the C-terminus; the successor to elamipretide from the same developer.

What it's used for

An investigational mitochondrial-targeting compound, studied in neurodegeneration and now in eye disease. Approved nowhere.

02

How does Bevemipretide (SBT-272) work?

What it does in the body, and where.

Cardiolipin is a lipid found almost nowhere except the inner membrane of mitochondria, where it holds the energy-producing machinery in the right arrangement. When it is damaged or mislocated, that machinery falls apart. A family of small positively charged molecules binds cardiolipin and appears to hold the structure together, and this is the second of them from the same developer.

  1. 01
    It is built like a peptide, with two unusual residues
    The backbone is D-arginine, then 2,6-dimethyltyrosine, then a residue with a lysine-like side chain. D-arginine is the mirror image of the natural amino acid, which resists breakdown by enzymes that only recognize the natural form, and the dimethylated tyrosine is likewise not something a ribosome makes.
  2. 02
    The tail is a ring, not an amide
    Where a peptide would end in a carboxyl or an amide, this molecule ends in a benzyl-substituted 1,2,4-oxadiazole ring. Swapping a peptide bond for a heterocycle is the standard way to make something behave like a peptide while surviving in the body longer. It is also the single feature that makes the classification arguable.
  3. 03
    The design goal was the brain
    The developer's first compound in this family, SS-31, does not cross into the brain usefully. This one is described across sources as brain-penetrant, and that is what the indications follow from: amyotrophic lateral sclerosis and dementias first, and more recently the eye, which is an outgrowth of the central nervous system.
  4. 04
    What has actually been shown
    Laboratory work reports that it improves TDP-43 pathology in upper motor neurons in amyotrophic lateral sclerosis models by restoring mitochondrial integrity, motility and function, and that it prevents stroke-induced mitochondrial dysfunction. In people, a subcutaneous phase 1 in healthy volunteers was completed and a phase 2/3 in dry age-related macular degeneration, given as a once-daily eye drop rather than an injection, was registered in November 2026. No efficacy result in a person has been published.
Anatomical illustration highlighting the whole body
WHAT THIS COMPOUND ACTS ON:
03

What else is it used for?

Each use below carries its own evidence level. Approved means regulators have cleared it for that purpose. Investigational means it is in trials. Early research means it is being studied and is not established.

  • Amyotrophic lateral sclerosis, the original indication, with orphan drug statustrial-protocol
  • Multiple system atrophy and frontotemporal dementia, listed development indicationsnone
  • Dry age-related macular degeneration and macular dystrophy, the current ophthalmic programtrial-protocol
  • Protection against stroke-induced mitochondrial dysfunction, from laboratory workEarly research

The published record

Research index

2

Papers about Bevemipretide (SBT-272) · this compound only

Searched: Bevemipretide, SBT-272.

Left out: SS-31 (the earlier compound from the same developer, which has its own page); elamipretide (that compound's other name); MTP-131 (that compound's development code); Bendavia (that compound's trade name); cardiolipin (the molecule it binds, with a large literature of its own); peptidomimetic (a chemistry term used across many unrelated drugs); 2356106-71-1 (the CAS number, which does not appear in titles or abstracts); 2589640-11-7 (the salt form's CAS number); F553HAL9V8 (a regulatory ingredient code that does not appear in papers).

2 papers tagged human · 1 not reviews or lab · 0 clinical trial publications

1 registered trials · none with posted results

Furthest stage reached: Phase 2, not yet recruiting

Compare this against the whole library →

In animals1
In the lab0
Reviews0
Senior author shareSpread across many groups

Evidence summary

Counted from Europe PMC indexing, not read by a person; a human tag can land on reviews, commentary or lab papers; clinical trial publications is the narrower count. A preprint and its journal version count once.

Bevemipretide (SBT-272) vial rendering
Compound field notes

At a glance

Four things to know about Bevemipretide (SBT-272)

01

Evidence

Investigational

02

Category

Longevity and energy

03

Common vial

Varies

04

Half-life

Not published

04

How much, and do you cycle it?

The range, and whether you take breaks.

1 percent or 2 percent eye drops once daily (phase 2/3), once daily in the study eye. Not established No range

No dose, schedule or course length has been published for any indication, so nothing can be said about how it would be taken.

Compare this against the whole library →

05

How long does it stay in the body?

The half-life, and where the figure comes from.

Not publishedNo figure

No pharmacokinetic figures have been published. A phase 1 in healthy subjects would have generated them, but no results from it were read at source during this review. The structural features of the molecule, the D-amino acid and the oxadiazole in place of a terminal amide, are the kind that lengthen exposure, but that is an inference from chemistry rather than a measurement.

You can compare this against the whole library to see where it sits.

06

How do I dose and price it?

Enter your vial and your dose. Pick a mix. We show the draw and the cost.

The vial holds a fixed amount of drug. Adding more water does not make more drug, it just spreads it thinner, so you draw a bigger number on the syringe for the same dose.

Your vial size (mg)
Enter the amount printed on your label.
What you paid per vial
$
Used for cost per dose only.
Your dose (mg)
Commonly referenced range: 1 up to 3 percentTrial dose

Choose your mix

mL water—units · —
Enter your own volume

Measuring the water1 mL = one full 100-unit syringe.

YOUR DRAW0 / 100 units
07

How do you store it?

Before mixing, and after.

Nothing to store: it is not sold anywhere.

Bevemipretide (SBT-272) has never been marketed, so there is no vial, pen or bottle to keep at home. Supplies for a trial are made, stored and dispensed by the sponsor and the trial pharmacy under conditions set in the protocol. Anything offered for sale under this name did not come from that supply chain.

08

What are the side effects and cautions?

Known cautions and warnings for this compound.

Who should avoid it

Check these before anything else.
  • Any use outside a clinical trial, because there is no approved product and no published dose
  • Treating it as interchangeable with SS-31, which is a different molecule with a different structure and a different clinical record
  • Any assumption that the eye program's existence implies the earlier neurology programs succeeded

Stop and get help

These are emergencies. Seek care.
  • Any allergic reaction, meaning rash, swelling of the face or lips, or trouble breathing
  • An injection site reaction that spreads, blisters or does not settle
  • Any new neurological or visual symptom while in a trial, which belongs to the trial team

Common effects

Expected, and usually mild.
  • No published adverse event profile was read at source during this review.
  • Described by the sponsor as well tolerated, which is a sponsor characterization rather than a published dataset.

Where this page says nothing is established, that means nobody has studied it, not that a compound is safe.

09

Is Bevemipretide (SBT-272) approved?

And where the numbers on this page come from.

No. Bevemipretide (SBT-272) is not approved anywhere and is currently in company-run clinical trials. There is no legal route to obtain it outside a trial.

What has happened recently

Investigational everywhere, approved nowhere. The United States drug substance registry records its approval year as unknown, meaning unapproved. It holds orphan drug status for amyotrophic lateral sclerosis. A first-in-human phase 1 of single and multiple ascending subcutaneous doses in healthy volunteers is registered as ISRCTN12414966 and recorded as completed; that record's ClinicalTrials.gov identifier field reads nil known, so the phase 1 has no NCT number. The current program is ophthalmic and it does have one: NCT07927010, the ReBUILD study, a phase 2/3 randomized, double-masked, vehicle-controlled, dose-ranging trial of once-daily bevemipretide ophthalmic topical solution in dry age-related macular degeneration, approximately 300 subjects randomized to low dose, high dose or vehicle for 48 weeks, internal code MYTX272AM-201, sponsored by Mighty Therapeutics. That is not a different company from the originator but the same one renamed: Stealth BioTherapeutics announced on 16 June 2026 that it would operate as Mighty Therapeutics. Everything published on this compound before mid-2026, including the eye drop phase 1 announcement and the earlier neurology work, carries the Stealth name, so a search under one name misses half the record. That record was read via a reproduction rather than at source, because ClinicalTrials.gov could not be opened during this review. No regulatory submission has been reported anywhere.

10

What else is like Bevemipretide (SBT-272)?

Others in Longevity and energy, side by side.

If you're weighing Bevemipretide (SBT-272), it's worth reading MOTS-c, Epitalon, and NAD+ in the same class.

Guides for this compound

Sources

  • United States drug substance registry record, SBT-272(2026)
    The United States drug substance registry record, read for the identifiers that settle what the molecule actually is. It gives the molecular formula C31H45N9O4, molecular weight 607.7469, three of three defined stereocenters, unique ingredient identifier F553HAL9V8, bevemipretide as the official international nonproprietary name, SBT-272 as the preferred name, and the systematic names D-arginyl-N-[(1S)-5-amino-1-(3-benzyl-1,2,4-oxadiazol-5-yl)pentyl]-2,6-dimethyl-L-tyrosinamide and the corresponding IUPAC form. The approval year is recorded as unknown, meaning unapproved.
  • IUPAC/BPS Guide to Pharmacology, bevemipretide ligand record(2026)
    A major pharmacology database, read for the classification question and cited as the source that calls it a peptide. It gives the synonyms SBT-272 and SBT272, states the compound class as Peptide, and describes bevemipretide as a modified tripeptide reading D-arginine, 2,6-dimethyltyrosine and a third residue, which helps stabilize the cardiolipin-rich inner mitochondrial membrane and promotes antioxidant, neuroprotective and mitochondria-protective effects in upper motor neurons. It records that the developer advanced the compound to early clinical evaluation in 2020 to determine safety and tolerability.
  • Alzheimer's Drug Discovery Foundation, Cognitive Vitality compound review, SBT-272(2026)
    A dementia research foundation's compound review, read as the source that calls it a peptidomimetic and for the development history. It describes SBT-272 as a novel peptidomimetic drug under development for amyotrophic lateral sclerosis and multiple system atrophy, records that no clinical trials had been completed and no observational studies existed at the time of writing, and states that in January 2020 a first-in-human phase 1 study of SBT-272 in 40 healthy subjects was initiated. It notes that the mechanism is similar to the developer's first-in-class lead compound SS-31, also known as elamipretide, and that SBT-272 interacts with cardiolipin, a lipid expressed exclusively on the inner mitochondrial membrane that organizes the electron transport chain into supercomplexes.
  • Patent and drug intelligence database entry, Bevemipretide(2026)
    A drug intelligence database entry, cited as the third classification and for the current indication list. It describes SBT-272 as a well-tolerated brain-penetrant small molecule that stabilizes cardiolipin, thereby restoring mitochondrial structure and respiratory function, gives the synonyms SBT 272 and SBT-272, records the highest development status as phase 1, and lists active indications of frontotemporal dementia, dry age-related macular degeneration and macular dystrophy. It also cites laboratory work reporting that SBT-272 improves TDP-43 pathology in amyotrophic lateral sclerosis upper motor neurons by modulating mitochondrial integrity, motility and function.
  • Drug chemistry reference compilation, Bevemipretide(2025)
    A drug chemistry reference compilation, read for the salt forms and the formal class designation. It records bevemipretide with CAS 2356106-71-1 as the free base and 2589640-11-7 for the trihydrochloride, molecular weight 607.7, formula C31H45N9O4, unique ingredient identifier F553HAL9V8 and the full systematic name. It lists the originator, classes the compound among peptidomimetics alongside antidementia and neuroprotectant categories, gives the mechanism as cardiolipin modulation and reactive oxygen species inhibition, and records orphan drug status for amyotrophic lateral sclerosis with phase 1 status in that indication and preclinical status in dry age-related macular degeneration.
  • Registry record NCT07927010, ReBUILD phase 2/3, read via a reproduction(2026)
    The ophthalmic trial registration, read via a reproduction because ClinicalTrials.gov could not be opened during this review. It is titled A Clinical Trial to Evaluate the Efficacy and Safety of Bevemipretide Ophthalmic Topical Solution in Subjects Who Have Dry Age-Related Macular Degeneration, with the acronym ReBUILD and the internal code MYTX272AM-201, sponsored by Mighty Therapeutics. The official title gives it as a phase 2/3, randomized, double-masked, vehicle-controlled, dose-ranging trial of once daily bevemipretide ophthalmic topical solution. Approximately 300 subjects with eligible dry age-related macular degeneration are randomized to one of three groups, low dose bevemipretide, high dose bevemipretide or vehicle, for daily ophthalmic administration over 48 weeks, with 1 percent bevemipretide named among the study drugs. This is the record that confirms the compound's current program is topical to the eye rather than injected.
  • Registry record ISRCTN12414966, SBT-272 phase 1 in healthy volunteers, read via a reproduction(2022)
    The phase 1 registration, read via a reproduction, and cited because it is on a different registry from the one people look in. It is held by the ISRCTN registry as ISRCTN12414966, titled a study in healthy volunteers to look at the safety and tolerability of the test medicine SBT-272 and how it is taken up by the body when given as single and multiple doses, with the formal title a phase I, randomized, double-blind, placebo-controlled, single and multiple ascending dose-escalation study. Sponsor code SBT272-102. Submission date 2 March 2022, marked prospectively registered, condition category nervous system diseases, status no longer recruiting and completed. Its ClinicalTrials.gov identifier field reads nil known, so this study has no NCT number. A drug intelligence database independently lists ISRCTN12414966 against this compound and records the route as subcutaneous injection.
  • Stealth BioTherapeutics, completion of enrollment in the bevemipretide eye drop phase 1, 27 April 2026(2026)
    The developer's announcement that the eye drop phase 1 had completed enrollment, read as a company document and cited for the trial's design and for the company name at the time. Dated 27 April 2026 and issued under the name Stealth BioTherapeutics, it describes a phase 1 single ascending dose and 28-day multiple ascending dose escalation trial in which Part A consists of three single-dose cohorts of six healthy volunteers each, receiving one drop of topical bevemipretide at 1, 2 or 3 percent or vehicle. It names the poster to be presented at the June 2026 vision research meeting as Bevemipretide Eye Drops for Dry AMD: A Phase 1 Dose Escalation Trial to Evaluate Safety, Tolerability, and Pharmacokinetics, and describes the compound as a mitochondrial cardiolipin binder developed as an eye drop reaching the retinal pigment epithelium and photoreceptors. The identical release later appears on the renamed company's own site.
  • Bevemipretide Eye Drops for Dry AMD: A Phase 1 Dose Escalation Study to Evaluate Safety, Tolerability, and Pharmacokinetics, ARVO 2026 abstract(2026)
    The conference abstract reporting the eye drop phase 1 result, read via a reproduction. Published in Investigative Ophthalmology and Visual Science, June 2026, volume 67, page 143, by DiMatteo, Wakefield, Brostowin, Bergheanu and Abbruscato. It describes a phase 1 single and 28-day multiple ascending dose escalation study in healthy subjects, with Part A of three single-dose cohorts of six subjects each, and reports that following single doses of 1, 2 or 3 percent topical bevemipretide, systemic exposure was low with no evidence of safety or tolerability concerns. Its stated purpose was to determine a safe and tolerable concentration range for subsequent studies in patients. A companion abstract from the previous year's meeting sets out the trial design derived from a 13-week animal safety study. No registry record for this eye drop phase 1 was located during this review, at ClinicalTrials.gov or at ISRCTN, so no identifier is recorded for it.
  • Mighty Therapeutics, Formerly Stealth BioTherapeutics, Announces New Name, 16 June 2026(2026)
    The company name change, read via a reproduction and cited for one fact. Dated 16 June 2026, it records that Stealth BioTherapeutics Holdings announced it would now operate as Mighty Therapeutics. An independent list of renamed biotechnology companies records the same change to June 2026, and the former company's own website now states that Stealth BioTherapeutics is now Mighty Therapeutics.

Beyond these, 3 records are indexed for this compound. Browse the records